| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Clinical perspectives, assessment, and mechanisms of metabolic associated fatty liver disease in patients with COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alejandro Campos-Murguía, Berenice M Román-Calleja, José A González-Regueiro, Ivonne Hurtado-Díaz-de-León, Alberto Adrián Solís-Ortega, Nayelli C Flores-García, Ignacio García-Juárez, Astrid Ruiz-Margáin and Ricardo Ulises Macías-Rodríguez |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ricardo Ulises Macías-Rodríguez, MD, MSc, PhD, Assistant Professor, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Mexico City 14080, Mexico. ricardomacro@yahoo.com.mx |
| Key Words |
Metabolic associated fatty liver disease; COVID-19; Mortality; Fibrosis; Histology; Epidemiology |
| Core Tip |
The coronavirus disease 2019 (COVID-19) pandemic arrives amid a population increasingly affected by metabolic diseases such as DM2 and metabolic associated fatty liver disease (MAFLD). Patients with MAFLD can have chronic inflammation, endothelial dysfunction, and higher expression of angiotensin-converting enzyme 2 receptor, which could synergize with severe acute respiratory syndrome coronavirus 2 pathophysiology, predisposing a greater risk of adverse outcomes. Interestingly a high prevalence of liver steatosis in postmortem samples of patients who had COVID-19 has been found. Moreover, the presence of liver fibrosis has been shown to worsen prognosis in these patients, as a result, all patients with COVID-19 should be assessed for the presence of these comorbidities and given a closer follow-up. |
| Publish Date |
2021-09-03 11:45 |
| Citation |
Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i33/5502.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i33.5502 |
